Caribou Biosciences Profit Margin

The latest profit margin for CRBU is -2016.03% as of March 2026. That compares with -1954.55% in the prior-year period — down 3.1% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Caribou Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRBU's profit margin moved from -1954.55% to -2016.03% — a 3.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Caribou Biosciences's valuation or profitability profile.

Against Healthcare companies, CRBU currently prints -2016.03% for profit margin, while the sector average sits near 14.34%. That is roughly 14154.1% below the sector mean. Large gaps often invite a closer look at Caribou Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Caribou Biosciences converts resources into returns. At -2016.03%, CRBU may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1954.55% in the prior-year period — down 3.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CRBU's profit margin (-2016.03%), review year-over-year change from -1954.55%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.